Vincristine Treatment Protects Against Podocyte Damage in Focal Segmental Glomerulosclerosis
Vincristine protects against pathological changes induced by FSGS serum, with preservation of tubulin and F-actin organization in podocytes. Understanding whether vincristine exerts similar effects in other patients with FSGS warrants further investigation to advance our knowledge of this alternative therapeutic.
Authors
- Marilina Antonelou (ORCID: https://orcid.org/0000-0001-6653-7511)
- Alan David Salama (ORCID: https://orcid.org/0000-0002-9255-9092)
- William J. Mason (ORCID: https://orcid.org/0000-0001-6014-3562)
- Alice Gage
- Stefano Da Sacco (ORCID: https://orcid.org/0000-0001-9654-6822)
- Laura Perin (ORCID: https://orcid.org/0000-0002-6955-6416)
- Karen Price (ORCID: https://orcid.org/0000-0002-8113-1461)
- Gideon Pomeranz (ORCID: https://orcid.org/0000-0001-9112-2924)
- David A. Long (ORCID: https://orcid.org/0000-0001-6580-3435)
- Jennifer C. Chandler (ORCID: https://orcid.org/0000-0001-9785-4528)
- Scott R Henderson
- Ruth J. Pepper
Institutions
- University of Southern California (US)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1016/j.ekir.2025.08.002
- Citations
- 3
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 4.29
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Kidney Research UK
- Great Ormond Street Hospital for Children
- Centro Singular de Investigación de Galicia
- Medical Research Council
- NIHR Great Ormond Street Hospital Biomedical Research Centre